Shows & Panels
- AFCEA Answers
- Ask the CIO
- The Big Data Dilemma
- Carrying On with Continuity of Operations
- Connected Government
- Constituent Servicing
- Continuous Monitoring: Tools and Techniques for Trustworthy Government IT
- The Cyber Imperative
- Cyber Solutions for 2013 and Beyond
- The Data Privacy Imperative: Safeguarding Sensitive Data
- Expert Voices
- Federal Executive Forum
- Federal IT Challenge
- Federal Tech Talk
- Mission-critical Apps in the Cloud
- The Modern Federal Threat Landscape
- The Path from Legacy Systems
- The Real Deal on Digital Government
- The Reality of Continuous Monitoring... Is Your Agency Secure?
- Veterans in Private Sector: Making the Transition
Shows & Panels
Feds probe link between opioid injections, clots
Friday - 10/26/2012, 11:35pm EDT
ATLANTA (AP) - Federal authorities say they are working with Tennessee officials to investigate why at least 12 patients in that state who injected the pain reliever Opana ER for non-medical reasons since February have a rare blood disorder.
The Centers for Disease Control and Prevention issued the health advisory Friday night regarding the pain reliever, an extended-release form of oxymorphone. The CDC is working with the Food and Drug Administration and the Tennessee Department of Health.
The investigation is focusing on a cluster of patients with Thrombotic Thrombocytopenic Purpura, described by officials as a blood disorder in which clots form in small blood vessels throughout the body. It is an uncommon but serious illness.
Authorities say Opana ER is only supposed to be taken orally. The cases were reported in Tennessee from April 16 to Oct. 19. Most of the women did not have a prescription and reported a history of chronic IV use of the opioid pain reliever for nonmedical reasons. All of the women were hospitalized, but no deaths have occurred.
(Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)